Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma

JAMA Oncol. 2024 May 1;10(5):674. doi: 10.1001/jamaoncol.2024.0116.

Authors

Ryan Sun¹, Jose M Moraleda², Lee-Jen Wei³

Affiliations

¹ Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
² Hematology and Advanced Therapies Department, University Hospital Virgen de la Arrixaca, Murcia, Spain.
³ Department of Biostatistics, Harvard University, Boston, Massachusetts.

PMID: 38483380
DOI: 10.1001/jamaoncol.2024.0116

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / pathology
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Sorafenib* / therapeutic use
Treatment Outcome

Substances

tislelizumab